97 related articles for article (PubMed ID: 26240228)
1. Is C-Reactive Protein a Specific Marker in Melanoma?
Li Z; Feng J; Sun X
J Clin Oncol; 2015 Nov; 33(31):3673-4. PubMed ID: 26240228
[No Abstract] [Full Text] [Related]
2. Reply to Z. Li et al.
Fang S; Wang Y; Amos CI; Lee JE
J Clin Oncol; 2015 Nov; 33(31):3674-5. PubMed ID: 26240223
[No Abstract] [Full Text] [Related]
3. [Colon tumor and inflammation: is C-reactive protein possible colon tumor marker?].
Myung SJ
Korean J Gastroenterol; 2008 Apr; 51(4):265-8. PubMed ID: 18516007
[No Abstract] [Full Text] [Related]
4. D-dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress.
Desch A; Gebhardt C; Utikal J; Schneider SW
Int J Cancer; 2017 Feb; 140(4):914-921. PubMed ID: 27813063
[TBL] [Abstract][Full Text] [Related]
5. Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma.
Chasseuil E; Saint-Jean M; Chasseuil H; Peuvrel L; Quéreux G; Nguyen JM; Gaultier A; Varey E; Khammari A; Dréno B
Acta Derm Venereol; 2018 Apr; 98(4):406-410. PubMed ID: 29327065
[TBL] [Abstract][Full Text] [Related]
6. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
Findeisen P; Zapatka M; Peccerella T; Matzk H; Neumaier M; Schadendorf D; Ugurel S
J Clin Oncol; 2009 May; 27(13):2199-208. PubMed ID: 19307507
[TBL] [Abstract][Full Text] [Related]
7. Serum long non-coding RNA, snoRNA host gene 5 level as a new tumor marker of malignant melanoma.
Ichigozaki Y; Fukushima S; Jinnin M; Miyashita A; Nakahara S; Tokuzumi A; Yamashita J; Kajihara I; Aoi J; Masuguchi S; Zhongzhi W; Ihn H
Exp Dermatol; 2016 Jan; 25(1):67-9. PubMed ID: 26440365
[No Abstract] [Full Text] [Related]
8. The prognostic role of detection of circulating melanoma cells in the blood.
Dutcher JP
J Clin Oncol; 2003 Mar; 21(5):757-9. PubMed ID: 12610168
[No Abstract] [Full Text] [Related]
9. Correlation between lipid-associated sialic acid and tumor burden in melanoma.
Buzaid AC; Sandler AB; Hayden CL; Scinto J; Poo WJ; Clark MB; Hotchkiss S
Int J Biol Markers; 1994; 9(4):247-50. PubMed ID: 7836804
[TBL] [Abstract][Full Text] [Related]
10. Circulating epigenetic biomarkers in melanoma.
Xin Y; Li Z; Chan MT; Wu WK
Tumour Biol; 2016 Feb; 37(2):1487-92. PubMed ID: 26662802
[TBL] [Abstract][Full Text] [Related]
11. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma.
Mårtenson ED; Hansson LO; Nilsson B; von Schoultz E; Månsson Brahme E; Ringborg U; Hansson J
J Clin Oncol; 2001 Feb; 19(3):824-31. PubMed ID: 11157036
[TBL] [Abstract][Full Text] [Related]
12. Tumor biomarkers in melanoma.
Ugurel S; Utikal J; Becker JC
Cancer Control; 2009 Jul; 16(3):219-24. PubMed ID: 19556961
[TBL] [Abstract][Full Text] [Related]
13. Serum lactate dehydrogenase is a more useful biomarker of prognosis than serum S100B in patients with BRAF-mutant melanoma.
Sullivan RJ
Br J Dermatol; 2016 Apr; 174(4):716-7. PubMed ID: 27115584
[No Abstract] [Full Text] [Related]
14. Circulating biomarkers in malignant melanoma.
Alegre E; Sammamed M; Fernández-Landázuri S; Zubiri L; González Á
Adv Clin Chem; 2015; 69():47-89. PubMed ID: 25934359
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of hepatocyte growth factor as a potential tumor marker in patients with malignant melanoma.
Hügel R; Muendlein A; Volbeding L; Drexel H; Richtig E; Wehkamp U; Painsi C; Lange-Asschenfeldt B; Hauschild A; Egberts F
Melanoma Res; 2016 Aug; 26(4):354-60. PubMed ID: 27206057
[TBL] [Abstract][Full Text] [Related]
16. Heterogenous S-100B protein expression patterns in malignant melanoma and association with serum protein levels.
Bánfalvi T; Udvarhelyi N; Orosz Z; Gergye M; Gilde K; Tímár J
Oncology; 2003; 64(4):374-9. PubMed ID: 12759535
[TBL] [Abstract][Full Text] [Related]
17. [Some immunological findings in malignant melanoma (author's transl)].
Richter J; Král V; Duchková H; Kubíková M
Cesk Dermatol; 1980 Feb; 55(1):12-8. PubMed ID: 6965892
[No Abstract] [Full Text] [Related]
18. Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein.
Fang S; Sui D; Wang Y; Liu H; Chiang YJ; Ross MI; Gershenwald JE; Cormier JN; Royal RE; Lucci A; Wargo J; Hu MI; Gardner JM; Reveille JD; Bassett RL; Wei Q; Amos CI; Lee JE
J Clin Oncol; 2016 May; 34(15):1741-7. PubMed ID: 27001565
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma.
Calapre L; Warburton L; Millward M; Ziman M; Gray ES
Cancer Lett; 2017 Sep; 404():62-69. PubMed ID: 28687355
[TBL] [Abstract][Full Text] [Related]
20. Search for melanoma markers in plasma and serum samples.
Seraglia R; Vogliardi S; Allegri G; Comai S; Lise M; Rossi CR; Mocellin S; Scalerta R; Ragazzi E; Traldi P
Eur J Mass Spectrom (Chichester); 2005; 11(3):353-60. PubMed ID: 16107750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
